Overview
Design and Analysis of Clinical Trials
Methods for Diagnostic and Predictive Medicine
Analysis of Data from Multiple Sources
Survival Analysis
Causal Inference
Current Duke Appointments & Affiliations
Professor of Biostatistics & Bioinformatics
·
2021 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Member of the Duke Cancer Institute
·
2015 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.
Journal article Int J Radiat Oncol Biol Phys · November 1, 2026 PURPOSE: We report mature outcomes of patients with limited-stage small cell lung cancer randomly assigned to the 61.2 Gy concomitant boost (CB) thoracic radiation therapy (TRT) arm of Cancer and Leukemia Group B (CALGB) 30610/Radiation Therapy Oncology Gr ... Full text Link to item CiteOutcomes Based on Age in CALGB 140503 (Alliance): Lobar Versus Sublobar Resection for Peripheral Stage IA Non-small Cell Lung Cancer.
Journal article Clin Lung Cancer · September 2026 OBJECTIVE: In CALGB trial 140503, sublobar resection was not inferior to lobar resection for T1aN0 (size ≤ 2 cm) non-small cell lung cancer (NSCLC) patients. This analysis compares the effect of age on outcomes with the 2 approaches. METHODS: Patients (N = ... Full text Link to item CiteCHIO3: CHemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B (N2) Non-Small Cell Lung Cancer: Surgical Outcomes.
Journal article Ann Thorac Surg · August 5, 2026 BACKGROUND: There is renewed interest in resection of Stage III (N2+) NSCLC given impressive outcomes with neoadjuvant/perioperative chemoimmunotherapy (ChIO). We report surgical outcomes from an exclusively N2+ NSCLC clinical trial following chemotherapy ... Full text Link to item CiteRecent Grants
AFT-61 Stats
ResearchPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2025 - 2030Towards ML-Powered, Efficient and Robust Inference of Average and Individual Treatment Effects for Novel Clinical Trials in Rare Diseases
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2026 - 2030AFT-57 Trials (5d)
ResearchPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2023 - 2028View All Grants
Education
University of North Carolina, Chapel Hill ·
2003
Ph.D.